Product
Debio 1347
1 clinical trial
1 indication
Indication
Solid TumorClinical trial
A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3Status: Terminated, Estimated PCD: 2020-12-31